About NanoString
NanoString is a company based in Seattle (United States) founded in 2003 by Dwayne Dunaway was acquired by Bruker in April 2024. NanoString has raised $107.93 million across 15 funding rounds from investors including SVB, Morgan Stanley and Blackstone. NanoString operates in a competitive market with competitors including Horizon Discovery, GSK, Avidity Biosciences, Quanterix and Sutro Biopharma, among others.
- Headquarter Seattle, United States
- Founders Dwayne Dunaway
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of NanoString
Unlock access to complete
Funding Insights of NanoString
NanoString has successfully raised a total of $107.93M across 15 strategic funding rounds. The most recent funding activity was a Post-IPO round of $200 million completed in March 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in NanoString
NanoString has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include SVB, Morgan Stanley and Blackstone.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
CRG is recognized as a premier healthcare investment partner.
|
Locked | Locked | Locked | |
|
Diversified investment management is provided across multiple asset classes.
|
Locked | Locked | Locked | |
|
US focused VC firm
|
Locked | Locked | Locked |
Investor details for NanoString
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NanoString
Investment portfolio details for NanoString
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NanoString
Detailed financials for NanoString
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nanostring Comparisons
Peer comparison for NanoString
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NanoString
NanoString operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Horizon Discovery, GSK, Avidity Biosciences, Quanterix and Sutro Biopharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genetically modified cell lines are developed using AAV gene-editing platform.
|
|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Assay kits for ultra-sensitive biomarker detection are developed.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
Detailed competitors of NanoString
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nanostring
Complete news archive for NanoString
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NanoString
NanoString was founded in 2003 and raised its 1st funding round 1 year after it was founded.
NanoString is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
NanoString is a funded company, having raised a total of $107.93M across 15 funding rounds to date.
NanoString was founded in 2003 in Seattle, United States, within the life sciences sector. Tools for translational research and molecular diagnosis are offered through technologies that enable protein and RNA expression analysis. Key products include the GeoMx Digital Spatial Profiler for spatial profiling and the nCounter Analysis system, which utilizes patented molecular barcode technology for digital detection. Operations focus on supporting research and diagnostic applications in biotechnology.
NanoString's top competitors include Horizon Discovery, Sutro Biopharma and Synthego.
NanoString has 12 investors. Key investors include SVB, Morgan Stanley, Blackstone, General Electric, and Bruker.